Merck partners with Bayshore for melanoma treatment
Written by: Michelle Nicols
Bayshore HealthCare’s national network of infusion clinics has been selected to provide Merck’s new melanoma treatment, Keytruda (pembrolizumab). The drug recently received its approval from Health Canada, and the program has begun to enroll its first patients.
“My team will handle patient support services, case management, referrals from physicians, and reimbursement,” says Shelley Burnett, Director of Operations, BSRx Patient Support Services. “It’s a good fit because Bayshore has strong nursing and infusion skills, and we’re an expert in the oncology field. Our philosophy and values put patients at the centre of our approach. We can’t be successful unless patients have a positive experience.”